Gyre Therapeutics Inc (GYRE)

Jun 08, 2026

Gyre therapeutics COO Ye Weiguo sells $218,561 in stock By Investing.com - Investing.com India

Jun 08, 2026

Jun 08, 2026

Gyre therapeutics COO Ye Weiguo sells $218,561 in stock - Investing.com

Jun 08, 2026

Jun 08, 2026

GYRE (GYRE) COO exercises options, sells 34,976 shares but keeps 700,000 - Stock Titan

Jun 08, 2026

Jun 03, 2026

Gyre Therapeutics Updates Post-Cullgen Acquisition Growth Strategy - The Globe and Mail

Jun 03, 2026

Jun 02, 2026

Gyre updates corporate presentation detailing pipeline, China strategy and regulatory progress - TradingView

Jun 02, 2026

Jun 02, 2026

Gyre Therapeutics (NASDAQ: GYRE) details F351 liver fibrosis data and degrader programs - Stock Titan

Jun 02, 2026

May 31, 2026

New strong sell stocks for May 27th - MSN

May 31, 2026

May 29, 2026

Gyre Therapeutics (GYRE) Gains Momentum: Price Nears Key Resistance at $6.21Equal Weight ETF - The Legal Advocate

May 29, 2026

May 29, 2026

Gyre Therapeutics (GYRE) Holds Steady at $5.74, Testing Key Support ZoneInside Day Breakout - The Legal Advocate

May 29, 2026

May 28, 2026

GYRE SEC FilingsGyre Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

May 28, 2026

May 28, 2026

GYRE Q1 2026 Earnings: Narrower-Than-Expected Loss Surprises AnalystsRevenue Guidance Range - The Legal Advocate

May 28, 2026

May 28, 2026

China regulator accepts Gyre’s liver fibrosis drug application By Investing.com - Investing.com Nigeria

May 28, 2026

May 28, 2026

Gyre Therapeutics (GYRE) Declines 3.1% as Stock Tests Key Support Near $5.45Gap Up Stocks - The Legal Advocate

May 28, 2026

May 28, 2026

US High Growth Tech Stocks To Watch - simplywall.st

May 28, 2026

May 27, 2026

Law firm investigates Gyre Therapeutics for possible securities law violations and breaches of fiduciary duty. - Pluang

May 27, 2026

May 27, 2026

Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm - TMX Newsfile

May 27, 2026

May 27, 2026

Gyre Therapeutics COO Ye Weiguo sells $45,680 in stock By Investing.com - Investing.com Nigeria

May 27, 2026

May 27, 2026

Gyre Therapeutics COO Ye Weiguo sells $45,680 in stock - Investing.com

May 27, 2026

May 27, 2026

COO of GYRE Therapeutics (NASDAQ: GYRE) sells shares after option exercises - Stock Titan

May 27, 2026

May 27, 2026

New Strong Sell Stocks for May 27th - Yahoo Finance

May 27, 2026

May 26, 2026

Gyre Therapeutics Inc. (GYRE) Edges Lower, Testing Key Support LevelsMedian Line - The Legal Advocate

May 26, 2026

May 26, 2026

GYRE Q1 2026 Earnings: Smaller-than-Expected Loss Drives Positive Surprise Amid Revenue AbsenceProfit Margin Analysis - The Legal Advocate

May 26, 2026

May 23, 2026

GYRE Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Pre-Revenue Stage - Newser

May 23, 2026

May 23, 2026

Gyre therapeutics COO Ye Weiguo’s $136,653 stock sale By Investing.com - Investing.com India

May 23, 2026

May 22, 2026

Gyre therapeutics COO Ye Weiguo’s $136,653 stock sale - Investing.com

May 22, 2026

May 22, 2026

GYRE (GYRE) COO sells 22,220 shares after stock option exercises - Stock Titan

May 22, 2026

May 21, 2026

Gyre Therapeutics COO Ye Weiguo sells $59,418 in shares By Investing.com - Investing.com India

May 21, 2026

May 20, 2026

Gyre Therapeutics (GYRE) director cancels 250,000-share stock option agreement - Stock Titan

May 20, 2026

May 20, 2026

Gyre Therapeutics COO Ye Weiguo sells $59,418 in shares - Investing.com

May 20, 2026

May 20, 2026

Gyre Therapeutics (GYRE) COO sells shares after exercising options - Stock Titan

May 20, 2026

May 19, 2026

Gyre Therapeutics (GYRE) Stock: Slides -2.17%, Support at $5.98 2026-05-19Advance Decline Volume - Newser

May 19, 2026

May 18, 2026

GYRE (GYRE) COO Ye exercises options and sells 28,680 shares in May - Stock Titan

May 18, 2026

May 17, 2026

Gyre Therapeutics (GYRE) Fell -6.43% — Is a Recovery Ahead? 2026-05-17Community Momentum Stocks - Newser

May 17, 2026

May 15, 2026

Gyre Therapeutics and Cullgen Advance CDK2-Cyclin E Degrader CG923308 for Treatment of Solid Tumors and CDK4/6i-Resistant Breast Cancer - Minichart

May 15, 2026

May 14, 2026

Gyre Therapeutics Highlights Cullgen Acquisition and Pipeline Expansion - TipRanks

May 14, 2026

May 14, 2026

Gyre Therapeutics to present CG923308 data; expects IND submission Q1 2027 - TradingView

May 14, 2026

May 14, 2026

Gyre Therapeutics (NASDAQ: GYRE) showcases degrader pipeline and CG923308 IND plans - Stock Titan

May 14, 2026

May 14, 2026

Gyre Therapeutics stock (KYG4200L1031): Low short interest signals stability amid pharma peers - AD HOC NEWS

May 14, 2026

May 13, 2026

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (Hydronidone) to Treat CHB-Induced Liver Fibrosis - Minichart

May 13, 2026

May 12, 2026

Gyre Therapeutics’ F351 NDA Accepted for Priority Review - TipRanks

May 12, 2026

May 12, 2026

Gyre Therapeutics announces NMPA acceptance of new drug application for F351 (hydronidone) - marketscreener.com

May 12, 2026

May 12, 2026

Gyre Therapeutics (GYRE) wins NMPA review acceptance for F351 liver fibrosis NDA - Stock Titan

May 12, 2026

May 12, 2026

GNI Group Reshapes Top Management as Gyre Advances Cullgen Acquisition - TipRanks

May 12, 2026

May 12, 2026

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment - The Manila Times

May 12, 2026

May 12, 2026

China regulator accepts Gyre’s liver fibrosis drug application - Investing.com India

May 12, 2026

May 12, 2026

New hepatitis B liver drug for China’s tens of millions enters NMPA review - Stock Titan

May 12, 2026

May 12, 2026

TradingKey - TradingKey

May 12, 2026